FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2033990131> ?p ?o ?g. }

• W2033990131 abstract "Patients with hypertension and cardiovascular disease (CVD), diabetes, or chronic kidney disease (CKD) usually require two or more antihypertensive agents to achieve blood pressure (BP) goals.The efficacy/safety of olmesartan (OM) 40 mg, amlodipine besylate (AML) 10 mg, and hydrochlorothiazide (HCTZ) 25 mg versus the component dual-combinations (OM 40/AML 10 mg, OM 40/HCTZ 25 mg, and AML 10/HCTZ 25 mg) was evaluated in participants with diabetes, CKD, or chronic CVD in the Triple Therapy with Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide in Hypertensive Patients Study (TRINITY). The primary efficacy end point was least squares (LS) mean reduction from baseline in seated diastolic BP (SeDBP) at week 12. Secondary end points included LS mean reduction in SeSBP and proportion of participants achieving BP goal (<130/80 mm Hg) at week 12 (double-blind randomized period), and LS mean reduction in SeBP and BP goal achievement at week 52/early termination (open-label period).At week 12, OM 40/AML 10/HCTZ 25 mg resulted in significantly greater SeBP reductions in participants with diabetes (-37.9/22.0 mm Hg vs -28.0/17.6 mm Hg for OM 40/AML 10 mg, -26.4/14.7 mm Hg for OM 40/HCTZ 25 mg, and -27.6/14.8 mm Hg for AML 10/HCTZ 25 mg), CKD (-44.3/25.5 mm Hg vs -39.5/23.8 mm Hg for OM 40/AML 10 mg, -25.3/17.0 mm Hg for OM 40/HCTZ 25 mg, and -33.4/20.6 mm Hg for AML 10/HCTZ 25 mg), and chronic CVD (-37.8/20.6 mm Hg vs -31.7/18.2 mm Hg for OM 40/AML 10 mg, -30.9/17.1 mm Hg for OM 40/HCTZ 25 mg, and -27.5/16.1 mm Hg for AML 10/HCTZ 25 mg) (P<0.05 for all subgroups vs dual-component treatments). BP goal achievement was greater for participants receiving triple-combination treatment compared with the dual-combination treatments, and was achieved in 41.1%, 55.0%, and 38.9% of participants with diabetes, CKD, and chronic CVD on OM 40/AML 10/HCTZ 25 mg, respectively. At week 52, there was sustained BP lowering with the OM/AML/HCTZ regimen. Overall, the triple combination was well tolerated.In patients with diabetes, CKD, or chronic CVD, short-term (12 weeks) and long-term treatment with OM 40/AML 10/HCTZ 25 mg was well tolerated, lowered BP more effectively, and enabled more participants to reach BP goal than the corresponding 2-component regimens. TRIAL IDENTIFICATION NUMBER: NCT00649389." @default.
• W2033990131 created "2016-06-24" @default.
• W2033990131 creator A5014478200 @default.
• W2033990131 creator A5025430476 @default.
• W2033990131 creator A5031212154 @default.
• W2033990131 creator A5042772507 @default.
• W2033990131 creator A5073233494 @default.
• W2033990131 creator A5076355849 @default.
• W2033990131 creator A5080569422 @default.
• W2033990131 creator A5082003758 @default.
• W2033990131 date "2012-10-30" @default.
• W2033990131 modified "2023-10-01" @default.
• W2033990131 title "Olmesartan/amlodipine/hydrochlorothiazide in participants with hypertension and diabetes, chronic kidney disease, or chronic cardiovascular disease: a subanalysis of the multicenter, randomized, double-blind, parallel-group TRINITY study" @default.
• W2033990131 cites W1558811601 @default.
• W2033990131 cites W1563484591 @default.
• W2033990131 cites W1891347785 @default.
• W2033990131 cites W1981612812 @default.
• W2033990131 cites W2009116023 @default.
• W2033990131 cites W2020817501 @default.
• W2033990131 cites W2040292058 @default.
• W2033990131 cites W2043244508 @default.
• W2033990131 cites W2044773944 @default.
• W2033990131 cites W2048695535 @default.
• W2033990131 cites W2054429282 @default.
• W2033990131 cites W2054796764 @default.
• W2033990131 cites W2056976690 @default.
• W2033990131 cites W2060892547 @default.
• W2033990131 cites W2061445891 @default.
• W2033990131 cites W2066167473 @default.
• W2033990131 cites W2070257555 @default.
• W2033990131 cites W2078297720 @default.
• W2033990131 cites W2084093198 @default.
• W2033990131 cites W2089661021 @default.
• W2033990131 cites W2094625675 @default.
• W2033990131 cites W2106320466 @default.
• W2033990131 cites W2110020527 @default.
• W2033990131 cites W2110880027 @default.
• W2033990131 cites W2126236710 @default.
• W2033990131 cites W2130483595 @default.
• W2033990131 cites W2136145230 @default.
• W2033990131 cites W2137978158 @default.
• W2033990131 cites W2156121263 @default.
• W2033990131 cites W2157677292 @default.
• W2033990131 cites W2171673811 @default.
• W2033990131 cites W2256300068 @default.
• W2033990131 cites W2303651371 @default.
• W2033990131 cites W2404212513 @default.
• W2033990131 cites W2480651174 @default.
• W2033990131 cites W2608915729 @default.
• W2033990131 cites W2615684303 @default.
• W2033990131 cites W3034899365 @default.
• W2033990131 cites W4231455521 @default.
• W2033990131 cites W4243553261 @default.
• W2033990131 cites W4378171839 @default.
• W2033990131 doi "https://doi.org/10.1186/1475-2840-11-134" @default.
• W2033990131 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3547771" @default.
• W2033990131 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23110471" @default.
• W2033990131 hasPublicationYear "2012" @default.
• W2033990131 type Work @default.
• W2033990131 sameAs 2033990131 @default.
• W2033990131 citedByCount "29" @default.
• W2033990131 countsByYear W20339901312013 @default.
• W2033990131 countsByYear W20339901312014 @default.
• W2033990131 countsByYear W20339901312015 @default.
• W2033990131 countsByYear W20339901312016 @default.
• W2033990131 countsByYear W20339901312017 @default.
• W2033990131 countsByYear W20339901312018 @default.
• W2033990131 countsByYear W20339901312019 @default.
• W2033990131 countsByYear W20339901312020 @default.
• W2033990131 countsByYear W20339901312021 @default.
• W2033990131 countsByYear W20339901312022 @default.
• W2033990131 countsByYear W20339901312023 @default.
• W2033990131 crossrefType "journal-article" @default.
• W2033990131 hasAuthorship W2033990131A5014478200 @default.
• W2033990131 hasAuthorship W2033990131A5025430476 @default.
• W2033990131 hasAuthorship W2033990131A5031212154 @default.
• W2033990131 hasAuthorship W2033990131A5042772507 @default.
• W2033990131 hasAuthorship W2033990131A5073233494 @default.
• W2033990131 hasAuthorship W2033990131A5076355849 @default.
• W2033990131 hasAuthorship W2033990131A5080569422 @default.
• W2033990131 hasAuthorship W2033990131A5082003758 @default.
• W2033990131 hasBestOaLocation W20339901311 @default.
• W2033990131 hasConcept C126322002 @default.
• W2033990131 hasConcept C126894567 @default.
• W2033990131 hasConcept C134018914 @default.
• W2033990131 hasConcept C2777180221 @default.
• W2033990131 hasConcept C2778653478 @default.
• W2033990131 hasConcept C2779646130 @default.
• W2033990131 hasConcept C2779766728 @default.
• W2033990131 hasConcept C2780361556 @default.
• W2033990131 hasConcept C555293320 @default.
• W2033990131 hasConcept C71924100 @default.
• W2033990131 hasConcept C84393581 @default.
• W2033990131 hasConcept C90924648 @default.
• W2033990131 hasConceptScore W2033990131C126322002 @default.
• W2033990131 hasConceptScore W2033990131C126894567 @default.
• W2033990131 hasConceptScore W2033990131C134018914 @default.
• W2033990131 hasConceptScore W2033990131C2777180221 @default.
• W2033990131 hasConceptScore W2033990131C2778653478 @default.
• W2033990131 hasConceptScore W2033990131C2779646130 @default.

• next